CClinicalTrials.gg
CompletedNCT06934993Updated Jul 8, 2025Results posted

Comparison of Bidirectional Palpation Test and Transit Time Flow Measurement for LIMA-LAD Graft Patency

An observational study in Coronary Arterial Disease (CAD), Coronary Artery Bypass and LIMA, sponsored by Abdulgani Orhun YENİGÜN. Completed at 1 site in Turkey (Türkiye). Open to participants aged 41 Years to 81 Years. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Abdulgani Orhun YENİGÜN · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
116
Ages
41 Years to 81 Years
Sex
All
01

Study summary

The most important factor determining mortality and morbidity after coronary artery bypass graft (CABG) surgery is graft patency. The LIMA-LAD anastomosis is the most crucial anastomosis because it's revascularizing the most important and large region of the heart, has superior long-term graft patency rates and is considered the gold standard for CABG. Therefore, ensuring the patency of the LIMA-LAD anastomosis is vital for both early and late outcomes. The bidirectional palpation test (BPT), developed in our clinic to assess graft patency, is a subjective test, yet it is simple and reliable. Additionally, transit time flow meter (TTFM) measurements have also been performed. In this study, the efficacy of BPT and the results of TTFM measurements were compared by examining graft patency through early-period coronary CT angiography (CCTA).

Read the detailed description

STUDY DESIGN This study was designed as a retrospective-prospective hybrid cohort study. The study population was selected among patients who underwent LIMA-LAD anastomosis during CABG surgery at our clinic. Patients who wished to participate in the study gave informed consent by signing a preoperative consent form. Intraoperative BPT (Bidirectional Palpation Test) results and TTFM (Transit-Time Flow Measurement) values were recorded and compared with the early postoperative period (first month) CTCA (Coronary Tomography Angiography) findings. Data from 23 of the 73 patients included in the study were obtained retrospectively, while data from the remaining 50 patients were collected prospectively. All procedures performed on patients throughout the study were conducted in accordance with ethical standards, and patient information was kept confidential.

ETHICS COMMITTEE This study was conducted in accordance with the guidelines of the Clinical Research Ethics Committee of Istanbul University Cerrahpaşa and the principles outlined in the Declaration of Helsinki. In this retrospective-prospective hybrid cohort study, all data were anonymized. Throughout the study process, participant privacy and the protection of personal data were prioritized. Patient confidentiality was ensured in full compliance with ethical standards and relevant legal regulations. This approach ensured that ethical principles were maintained throughout the research process and that participants' rights were protected.

PATIENT SELECTION A total of 73 patients who underwent elective isolated CABG surgery or CABG in combination with other procedures such as valve surgery or ascending aorta surgery and gave informed consent were included in the study. However, 43 patients were excluded for reasons such as refusing to participate postoperatively, death in the early postoperative period (3 patients), or conditions like elevated postoperative creatinine that precluded CTCA. As a result, 73 patients remained in the final analysis, and a total of 73 LIMA grafts were evaluated. To minimize the impact of the anastomosis technique and quality on the study outcomes, all surgeries were performed by the same surgical team.

INTRAOPERATIVE PLANNING Following standard surgical preparation under general anesthesia, patients were properly draped. After a median sternotomy, pedicled LIMA and saphenous vein grafts were harvested. The patient was heparinized, and the Activated Clotting Time (ACT) was raised above 450 seconds. After opening the pericardium, arterial cannulation of the aorta and venous cannulation of the right atrium were performed, and cardiopulmonary bypass (CPB) was initiated. Diastolic arrest was achieved using antegrade cold Del Nido cardioplegia after applying the aortic cross-clamp. Once the distal anastomoses were completed, the cross-clamp was removed. Proximal anastomoses were performed on the beating heart using a side clamp. After de-airing and gradual reduction of flow, CPB was discontinued. Once the heart resumed circulation, a segment of the LIMA was stripped of surrounding tissue for measurement. With mean arterial pressure maintained above 60 mmHg, TTFM and ÇYPT assessments of the LIMA-LAD anastomosis were performed. If the BPT result on LIMA was positive and the flow rate and PI measured by TTFM were within acceptable ranges, TTFM measurements of the saphenous vein grafts were then conducted. Once acceptable TTFM values were confirmed for the SVGs as well, hemodynamic and arrhythmia monitoring continued. If hemodynamics remained stable, protamine was administered to neutralize heparin, and the heart was decannulated. After ensuring hemostasis, mediastinal and left thoracic drains were placed. Temporary epicardial pacing wires were inserted, the sternum was closed with wire sutures, and the subcutaneous and skin layers were closed anatomically to complete the surgery.

BIDIRECTIONAL PALPATION TEST AND TTFM MEASUREMENTS In this method, after completing the anastomoses, CPB is temporarily discontinued to create a pulse pressure, and a segment on the LIMA with a palpable pulse is identified. In the first step, the distal part of the palpated segment is occluded using a bulldog clamp or the surgeon's hand, and if the pulse persists, proximal flow is confirmed. This assesses the antegrade flow from the subclavian artery into the LIMA. In the second step, the distal occlusion is released, and a bulldog clamp or manual occlusion is applied proximally to the palpated area. If the pulse remains palpable, retrograde flow and indirectly, the patency of the LIMA-LAD anastomosis are confirmed . Due to venous valve structures preventing backflow, BPT cannot routinely be used on SVGs. However, in cases of valve insufficiency causing regurgitation in the graft, SVGs can also be evaluated using BPT.

DATA RECORDING Data collection was carried out in three stages. In the first stage, preoperative data were obtained by reviewing patient files. In the second stage, intraoperative Bidirectional Palpation Test results and TTFM (Transit-Time Flow Measurement) values were evaluated and recorded by the surgeon. During postoperative follow-ups, patients were called in for a check-up in the first week after discharge, and blood tests-including renal function tests-were performed. Based on the test results, patients deemed suitable for CTCA (Coronary Tomography Angiography) were scheduled for imaging within the first postoperative month, and their imaging procedures were monitored. In the third stage, CTCA results were reported by radiologist and recorded. Grafts showing more than 50% luminal stenosis were considered occluded. These steps were designed to enhance the accuracy and reliability of the data.

PATIENT FOLLOW-UP Patients included in the study were closely monitored in the cardiovascular surgery intensive care unit and on the ward during the postoperative period. Upon discharge, patients were prescribed necessary medications and provided with relevant recommendations. To prevent graft occlusion, all patients were routinely prescribed either dual or single antiplatelet therapy, cholesterol-lowering agents, beta-blockers to prevent arrhythmias, and anticoagulants when necessary. Compliance with these treatments was closely monitored. Each medication's purpose, possible side effects, and interactions with other drugs were explained to the patients in detail. As part of secondary prevention, risk factors such as obesity, smoking, hyperlipidemia, diabetes, and hypertension were addressed through both pharmacological treatment and lifestyle modifications. Routine follow-ups were scheduled on postoperative day 7, and at 1, 6, and 12 months using laboratory tests and imaging techniques.

STATISTICAL ANALYSIS The study data were analyzed using the SPSS 25.0 statistical software package. For descriptive analyses, frequency distributions and percentages were calculated, means were presented with standard deviations, and medians were shown with minimum and maximum values. Since the data did not follow a normal distribution, the Mann-Whitney U test and Kruskal-Wallis test were used for comparisons between groups. The relationships between categorical variables were evaluated using the Pearson Chi-square test. In 2x2 tables, when the expected value in at least one cell was less than 5, Fisher's exact Chi-square test was applied, and when any observed value ranged between 5 and 20, the Yates-corrected Chi-square test was used. ROC analysis was performed to determine cut-off values for certain variables. A p-value of less than 0.05 was considered statistically significant.

02

Conditions studied

  • Coronary Arterial Disease (CAD)
  • Coronary Artery Bypass
  • LIMA
  • Graft Patency
  • LAD (Left Anterior Descending) Coronary Artery Stenosis
  • Saphenous Vein Graft Patency
  • LIMA-LAD ANASTOMOSIS
  • LIMA GREFT PATENCY

Browse trials for

Keywords

  • GRAFT PATENCY
  • LIMA-LAD ANATOMOSIS
  • LIMA GRAFT PATENCY
  • SAPHENOUS VEİN GRAFT PATENCY
  • CABG
03

In context

Coronary Stenosis

302 studies on the registry are indexed under Coronary Stenosis; 63 are open to participants now.

This study's enrollment of 116 is below the median of 200 across 132 observational studies indexed under Coronary Stenosis.

Browse Coronary Stenosis studies →

Lead sponsor

This is the only study on the registry with Abdulgani Orhun YENİGÜN as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
41 Years to 81 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

73 patients who underwent coronary artery bypass surgery (CABG) and LIMA-LAD anastomosis

Inclusion criteria

  1. Elective Isolated CABG Surgery: Patients undergoing elective isolated coronary artery bypass grafting (CABG).
  2. CABG with Additional Cardiac Surgery: Patients who had CABG surgery in conjunction with other cardiac procedures.
  3. Informed Consent: Patients who provided informed consent to participate in the study.
  4. Postoperative Follow-Up: Patients who were followed up postoperatively and completed the necessary evaluations.
  5. CABG patients whose renal functions are suitable for CTA

Exclusion criteria

Exclusion Criteria:

Refusal to Participate: Patients who did not wish to participate in the study after being approached.

Death in Early Postoperative Period: Patients who died in the early postoperative period (3 patients).

Inability to Perform CABG: Patients for whom CABG could not be performed due to postoperative complications (e.g., elevated creatinine levels leading to inability to perform CABG, 43 patients).

Patients in whom CT angiography is not appropriate: Such as acute or chronic renal failure

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
116 participants (actual)
Target follow-up
1 Month
Patient registry
Yes

Groups and cohorts

  • Elective CABG Patients with LIMA-to-LAD Grafts

    This cohort consists of patients who underwent elective coronary artery bypass grafting (CABG) with a left internal mammary artery (LIMA) to left anterior descending artery (LAD) anastomosis, and who were evaluated using intraoperative TTFM and BDPT, followed by early postoperative CTA imaging.

06

What researchers measure

Primary outcomes

  1. Reliability of Bidirectional Palpation Test (BPT) in Evaluating LIMA-LAD Graft Patency

    The reliability of the Bilateral Palpation Test (BPT) in evaluating LIMA-LAD graft patency was assessed. As detailed in the Study Description section, participants were evaluated intraoperatively as BPT-positive or BPT-negative. Grafts were considered patent in BPT-positive participants and occluded in those with negative findings. In the early postoperative period, contrast-enhanced coronary CT angiography (CCTA), a validated method for assessing graft patency, was performed. The correlation between CCTA and BPT results was then analyzed to evaluate the reliability of the BPT.

    Time frame: Postoperative first month.

  2. Reliability of TTFM in Evaluating LIMA-LAD Graft Patency

    Mean Graft Flow (MGF) and Pulsatility Index (PI) were used in this study as TTFM parameters for evaluating graft patency. In the literature, there is no clear consensus on cut-off values for these parameters. Therefore, the values commonly used in the literature were statistically analyzed, and the values that gave the most significant results with our data were accepted as cut-off values. These cut-off values were determined to be 10 ml/min for MGF and 4.5 for PI.

    Time frame: Postoperative first month

Secondary outcomes

  1. Correlation Between Intraoperative TTFM and BPT Results

    Mean Graft Flow (MGF) and Pulsatility Index (PI) were used in this study as TTFM parameters for evaluating graft patency. In the literature, there is no clear consensus on cut-off values for these parameters. Therefore, the values commonly used in the literature were statistically analyzed, and the values that gave the most significant results with our data were accepted as cut-off values. These cut-off values were determined to be 10 ml/min for MGF and 4.5 for PI. LIMA-LAD graft patency was considered compromised when MGF was \<10 ml/min and/or PI was \>4.5, whereas an MGF \>10 ml/min and/or PI \<4.5 was interpreted in favor of graft patency.

    Time frame: postoperative first month.

  2. The Correlation of SYNTAX 1 and SYNTAX 2 Risk Scores With LIMA-LAD Graft Patency Was Evaluated.

    The correlation between preoperatively calculated SYNTAX 1 and SYNTAX 2 risk scores and LIMA-LAD graft patency, TTFM measurements and BPT was demonstrated. The SYNTAX I and SYNTAX II scores are risk assessment tools used to guide treatment decisions in patients with complex coronary artery disease. The SYNTAX I score is based solely on the anatomical complexity of coronary lesions observed during angiography. It categorizes patients into three risk groups: low (0-22), intermediate (23-32), and high (≥33).Higher SYNTAX I scores are associated with more complex coronary artery disease and worse clinical outcomes, often favoring coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI). The SYNTAX II score combines anatomical factors with clinical variables such as age, gender, left ventricular ejection fraction, creatinine clearance, and the presence of comorbidities like COPD and peripheral artery disease. This comprehensive score provides a personalized risk

    Time frame: postoperative first month.

07

Results

Posted Jul 8, 2025
Limitations and caveats
The number of patients participating in the study was limited because the study was single-center and its duration was determined as 1 year.

Participant flow

A total of 116 patients who underwent elective isolated CABG surgery or CABG in combination with other procedures such as valve surgery or ascending aorta surgery and gave informed consent were included in the study. The first patient was enrolled in the study on August 31, 2023 while the last patient was enrolled on August 27, 2024.

Participant flow — Overall Study
MilestoneElective CABG Patients With LIMA-to-LAD Grafts
Started116
Completed73
Not completed43
Withdrew: Withdrawal by subject29
Withdrew: Elevated postoperative creatinine level11
Withdrew: Death3

Outcome measures

PrimaryReliability of Bidirectional Palpation Test (BPT) in Evaluating LIMA-LAD Graft Patency

The reliability of the Bilateral Palpation Test (BPT) in evaluating LIMA-LAD graft patency was assessed. As detailed in the Study Description section, participants were evaluated intraoperatively as BPT-positive or BPT-negative. Grafts were considered patent in BPT-positive participants and occluded in those with negative findings. In the early postoperative period, contrast-enhanced coronary CT angiography (CCTA), a validated method for assessing graft patency, was performed. The correlation between CCTA and BPT results was then analyzed to evaluate the reliability of the BPT.

Time frame:
Postoperative first month.
Reported as:
Count of participants · Participants
Reliability of Bidirectional Palpation Test (BPT) in Evaluating LIMA-LAD Graft Patency
ParticipantsElective CABG Patients With LIMA-to-LAD Grafts
Patients with LIMA-LAD graft occlusion (CCTA)2
Patients with negative BPT2
Patients with BPT negativity and LIMA-LAD graft occlusion (CCTA)2
BPT negativity in patients with LIMA-LAD graft occlusion (CCTA)2
BPT positivity in patients with patent LIMA-LAD grafts (CCTA)71
Statistical analysis
  • Elective CABG Patients With LIMA-to-LAD Grafts · Chi-squared · p = <0.001 (Statistical significance was defined as cases where the p-value was below 0.05.)
PrimaryReliability of TTFM in Evaluating LIMA-LAD Graft Patency

Mean Graft Flow (MGF) and Pulsatility Index (PI) were used in this study as TTFM parameters for evaluating graft patency. In the literature, there is no clear consensus on cut-off values for these parameters. Therefore, the values commonly used in the literature were statistically analyzed, and the values that gave the most significant results with our data were accepted as cut-off values. These cut-off values were determined to be 10 ml/min for MGF and 4.5 for PI.

Time frame:
Postoperative first month
Reported as:
Count of participants · Participants
Reliability of TTFM in Evaluating LIMA-LAD Graft Patency
ParticipantsElective CABG Patients With LIMA-to-LAD Grafts
Patients with LIMA-LAD graft occlusion2
Patients with measured MGF<10ml/min3
Patients with measured PI>4,523
Patients with measured MGF<10ml/min and PI>4,53
Patients with measured MGF<10ml/min and PI<4,5 or MGF>10 and PI>4,520
Patients with measured MGF<10ml/min with LIMA-LAD graft occlusion2
Patients with measured MGF>10ml/min with patent LIMA-LAD graft70
Patients with measured PI>4,5 with LIMA-LAD graft occlusion2
Patients with measured PI<4,5 with patent LIMA-LAD graft50
Patients with measured MGF<10ml/min and PI>4,5 with LIMA-LAD graft occlusion2
Statistical analysis
  • Elective CABG Patients With LIMA-to-LAD Grafts · Chi-squared · p = 0.001 (Statistical significance was defined as cases where the p-value was below 0.05.)
  • Elective CABG Patients With LIMA-to-LAD Grafts · Chi-squared · p = 0.096 (Statistical significance was defined as cases where the p-value was below 0.05.)
  • Elective CABG Patients With LIMA-to-LAD Grafts · Chi-squared · p = <0.001 (Statistical significance was defined as cases where the p-value was below 0.05.)
SecondaryCorrelation Between Intraoperative TTFM and BPT Results

Mean Graft Flow (MGF) and Pulsatility Index (PI) were used in this study as TTFM parameters for evaluating graft patency. In the literature, there is no clear consensus on cut-off values for these parameters. Therefore, the values commonly used in the literature were statistically analyzed, and the values that gave the most significant results with our data were accepted as cut-off values. These cut-off values were determined to be 10 ml/min for MGF and 4.5 for PI. LIMA-LAD graft patency was considered compromised when MGF was \<10 ml/min and/or PI was \>4.5, whereas an MGF \>10 ml/min and/or PI \<4.5 was interpreted in favor of graft patency.

Time frame:
postoperative first month.
Reported as:
Count of participants · Participants
Correlation Between Intraoperative TTFM and BPT Results
ParticipantsTTFM Parameters in Patients With Negative BPT
The rate of MGF <10 mL/min among patients with a negative BPT.2
The rate of PI>4.5 among patients with a negative BPT.2
Statistical analysis
  • TTFM Parameters in Patients With Negative BPT · Chi-squared · p = 0.001 (Statistical significance was defined as cases where the p-value was below 0.05.)
  • TTFM Parameters in Patients With Negative BPT · Chi-squared · p = 0.096 (Statistical significance was defined as cases where the p-value was below 0.05.)
SecondaryThe Correlation of SYNTAX 1 and SYNTAX 2 Risk Scores With LIMA-LAD Graft Patency Was Evaluated.

The correlation between preoperatively calculated SYNTAX 1 and SYNTAX 2 risk scores and LIMA-LAD graft patency, TTFM measurements and BPT was demonstrated. The SYNTAX I and SYNTAX II scores are risk assessment tools used to guide treatment decisions in patients with complex coronary artery disease. The SYNTAX I score is based solely on the anatomical complexity of coronary lesions observed during angiography. It categorizes patients into three risk groups: low (0-22), intermediate (23-32), and high (≥33).Higher SYNTAX I scores are associated with more complex coronary artery disease and worse clinical outcomes, often favoring coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI). The SYNTAX II score combines anatomical factors with clinical variables such as age, gender, left ventricular ejection fraction, creatinine clearance, and the presence of comorbidities like COPD and peripheral artery disease. This comprehensive score provides a personalized risk

Time frame:
postoperative first month.
Reported as:
Count of participants · Participants
The Correlation of SYNTAX 1 and SYNTAX 2 Risk Scores With LIMA-LAD Graft Patency Was Evaluated.
ParticipantsElective CABG Patients With LIMA-to-LAD Grafts
SYNTAX I score — Low score18
SYNTAX I score — Interm score29
SYNTAX I score — High score26
SYNTAX II score — Low score33
SYNTAX II score — Interm score28
SYNTAX II score — High score12
SYNTAX I score distribution in patients with occluded LIMA-LAD grafts — Low score2
SYNTAX I score distribution in patients with occluded LIMA-LAD grafts — Interm score0
SYNTAX I score distribution in patients with occluded LIMA-LAD grafts — High score0
SYNTAX II score distribution in patients with occluded LIMA-LAD grafts — Low score1
SYNTAX II score distribution in patients with occluded LIMA-LAD grafts — Interm score1
SYNTAX II score distribution in patients with occluded LIMA-LAD grafts — High score0
SYNTAX I score distribution in patients with MGF<10 ml/min — Low score3
SYNTAX I score distribution in patients with MGF<10 ml/min — Interm score0
SYNTAX I score distribution in patients with MGF<10 ml/min — High score0
SYNTAX I score distribution in patients with BPT negativity — Low score2
SYNTAX I score distribution in patients with BPT negativity — Interm score0
SYNTAX I score distribution in patients with BPT negativity — High score0
Statistical analysis
  • Elective CABG Patients With LIMA-to-LAD Grafts · Chi-squared · p = 0.04 (Statistical significance was defined as cases where the p-value was below 0.05.)
  • Elective CABG Patients With LIMA-to-LAD Grafts · Chi-squared · p = 0.679 (Statistical significance was defined as cases where the p-value was below 0.05.)
  • Elective CABG Patients With LIMA-to-LAD Grafts · Chi-squared · p = 0.011 (Statistical significance was defined as cases where the p-value was below 0.05.)

Adverse events

Collected over Adverse event data were collected for 6 months postoperatively.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elective CABG Patients With LIMA-to-LAD Grafts3/116 (2.6%)0/116 (0%)11/116 (9.5%)
Most frequent other events
Most frequent other events
EventElective CABG Patients With LIMA-to-LAD Grafts
Renal dysfunctionRenal and urinary disorders11/116

Baseline characteristics

Age, Continuous
Age, Continuous(years)Elective CABG Patients With LIMA-to-LAD Grafts
Mean58.25 ± 7.76
Age, Continuous
Age, Continuous(years)Elective CABG Patients With LIMA-to-LAD Grafts
Median58 (41 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Elective CABG Patients With LIMA-to-LAD Grafts
Female14
Male59
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Elective CABG Patients With LIMA-to-LAD Grafts
Region of Enrollment
Region of Enrollment(participants)Elective CABG Patients With LIMA-to-LAD Grafts
Turkey73
Diabetes Mellitus (DM)
Diabetes Mellitus (DM)(Participants)Elective CABG Patients With LIMA-to-LAD Grafts
Count of participants40
Peripheral Artery Disease (PAD)
Peripheral Artery Disease (PAD)(Participants)Elective CABG Patients With LIMA-to-LAD Grafts
Count of participants6
Smoking
Smoking(Participants)Elective CABG Patients With LIMA-to-LAD Grafts
Count of participants50

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine
    Istanbul, Bakırköy 34149, Turkey (Türkiye)
09

References and documents

Related links

Study documents

  • Study protocol · Oct 11, 2024
  • Informed consent form · Oct 11, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

Supporting information: Study protocol, Sap, Icf, Csr

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06934993
Lead sponsor
Abdulgani Orhun YENİGÜN
Responsible party
Abdulgani Orhun YENİGÜN (Principal Investigator, Istanbul University - Cerrahpasa) — Sponsor-investigator
First posted
Apr 18, 2025
Start date
Aug 31, 2023
Primary completion
Aug 27, 2024
Completion
Sep 14, 2024
Results posted
Jul 8, 2025
Last update
Jul 8, 2025

Study contacts

Abdulgani Orhun yenigün
principal investigator · İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion